BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo BI 10773 high doseDrug: BI 10773 high doseDrug: BI 10773 low doseDrug: Placebo BI 10773 low dose
- First Posted Date
- 2010-05-27
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 7064
- Registration Number
- NCT01131676
- Locations
- 🇺🇸
1245.25.10077 Boehringer Ingelheim Investigational Site, Yardley, Pennsylvania, United States
🇺🇸1245.25.10056 Boehringer Ingelheim Investigational Site, Gilbert, Arizona, United States
🇺🇸1245.25.10200 Boehringer Ingelheim Investigational Site, Delray Beach, Florida, United States
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 17183
- Registration Number
- NCT01126437
- Locations
- 🇺🇸
205.452.01345 Boehringer Ingelheim Investigational Site, Lancaster, California, United States
🇺🇸205.452.01362 Boehringer Ingelheim Investigational Site, Tustin, California, United States
🇺🇸205.452.01133 Boehringer Ingelheim Investigational Site, St. Petersburg, Florida, United States
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 508
- Registration Number
- NCT01125566
- Locations
- 🇦🇹
Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz, Austria
🇦🇷Sanatorio Parque, Rosario, Argentina
🇺🇸Ironwood Cancer and Research Centers, Chandler, Arizona, United States
Efficacy and Safety of 3 Doses of Tiotropium Compared to Placebo in Adolescents (12 to 17 Yrs) With Moderate Asthma
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 105
- Registration Number
- NCT01122680
- Locations
- 🇺🇸
205.424.01006 Boehringer Ingelheim Investigational Site, Columbia, Missouri, United States
🇺🇸205.424.01007 Boehringer Ingelheim Investigational Site, Warrensburg, Missouri, United States
🇩🇪205.424.49004 Boehringer Ingelheim Investigational Site, Rosenheim, Germany
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
- Conditions
- Ovarian Neoplasms
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 110
- Registration Number
- NCT01121406
- Locations
- 🇧🇪
1230.18.32003 Boehringer Ingelheim Investigational Site, Brussel, Belgium
🇧🇪1230.18.32004 Boehringer Ingelheim Investigational Site, Edegem, Belgium
🇧🇪1230.18.32002 Boehringer Ingelheim Investigational Site, Gent, Belgium
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
- Conditions
- AdenocarcinomaCarcinoma, Non-Small-Cell Lung
- Interventions
- Drug: Gemcitabine+Cisplatin
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2018-12-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 364
- Registration Number
- NCT01121393
- Locations
- 🇨🇳
Xiangya Hospital, Central South University, Changsha, China
🇨🇳307 Hospital of PLA, Beijing, China
🇨🇳Beijing Chao-Yang Hospital, Beijing, China
Bioequivalence of Pramipexole Extended Release (PPX ER) 1.5mg x 1 Tablet Once Daily (q.d.) vs. PPX ER 0.375mg x 4 Tablets Under Fasted and Fed Conditions in Japanese Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Drug: PPX ER
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 28
- Registration Number
- NCT01119443
- Locations
- 🇯🇵
248.677.001 Boehringer Ingelheim Investigational Site, Sumida-ku, Tokyo, Japan
Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT01111331
- Locations
- 🇩🇪
1245.18.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2014-06-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT01111318
- Locations
- 🇷🇴
1245.13.40001 Boehringer Ingelheim Investigational Site, Timisoara, Romania
Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 295
- Registration Number
- NCT01108809
- Locations
- 🇷🇴
Boehringer Ingelheim Investigational Site 6, Baia Mare, Romania
🇷🇴Boehringer Ingelheim Investigational Site 10, Bucuresti, Romania
🇷🇴Boehringer Ingelheim Investigational Site 8, Braila, Romania